Evolutionary dynamics of HIV-induced subversion of the immune response

Immunological Reviews

Volumn 168, Issue , 1999, Pages 75-98

  Wodarz, Dominik ^a   Nowak, Martin A ^a  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; EVOLUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIREMIA;

EID: 0033058393     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01284.x     Document Type: Review

References (118)

1. 1. Loveday C, et al. HIV 1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-824.
2. 2. Nowak MA, et al. HIV results in the frame - results confirmed. Nature 1995;375:193-193.
3. 3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV 1 infection. Nature 1995;373:123-126.
4. 4. Wei XP, et al. Viral dynamics in human-immunodeficiency virus type-1 infection. Nature 1995;373:117-122.
5. 5. Schuurman R, et al. Rapid changes in human-immunodeficiency-virus type-1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
6. 6. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV 1 dynamics in vivo - virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
7. 7. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997;94:6971-6976
8. + lymphocytes in vivo. AIDS 1997;11:SI7-S24.
9. 9. Nowak MA, Anderson RM, McLean AR, Wolfs TFW, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-969.
10. 10. Wain-Hobson S. The fastest genome evolution ever described: HIV variation in situ. Curr Opin Genet Dev 1993;3:878-883
11. 11. Nowak MA, Bonhoeffer S, Shaw GM, May RM. Ami-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997;184:205-219.
12. 12. Kuiken CL, Dejong JJ, Baan E, Keulen W, Tersmette M, Goudsmit, J. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type-1 during transition of the viral biological phenotype. J Virol 1992;66:4622-4627.
13. 13. Zhang LQ, Mackenzie P, Cleland A, Holmes EC, Brown AJL, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type-1 upon primary infection. J Virol 1993;67:1772-1777.
14. 14. Zhu TF, et al. Genotypic and phenotypic characterisation of HIV-1 in patients with primary infection. Science 1993;261:1179-1181.
15. 15. Safrit JT, Lee A, Koup RA. Characterisation of HLA-B7-restricted cytotoxic T lymphocyte clones specific for the 3rd variable region of the HIV GP120, isolated from 2 patients during acute seroconversion. AIDS Res Hum Retroviruses 1994;10:S2-S33.
16. 16. Saag MS, et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988;334:440-444.
17. 17. Eigen M. The AIDS debate. Naturwissenschaften 1989;76:341-350.
18. 18. Balfe P, Simmonds P, Ludlam CA, Bishop JO, Brown AJL. 1990 Concurrent evolution of human-immunodeficiency-virus type-1 in patients infected from the same source - rate of sequence change and low-frequency of inactivating mutations. J Virol 1990;64:6221-6233.
19. 19. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition. Nature 1991;354:453-459.
20. 20. McMichael A, et al. Epitope variation and T-cell recognition. J Cell Biochem Suppl 1995;S21A:60.
21. 21. McMichael A, Goulder P, Rowlandjones S, Nowak M, Phillips R. HIV escapes from cytotoxic lymphocytes. Immunology 1996;89;SEI11.
22. 22. Borrow P, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
23. 23. Goulder PJR, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
24. 24. Price DA, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890-1895.
25. 25. Berger EA, et al. A new classification for HIV-1. Nature 1998;391:240.
26. 26. Doms RW, Moore JP. HIV-1 coreceptor use: a molecular window into viral tropism. Available from: URL: http://hiv-web.lanl.gov/HTML/reviews/doms.html.
27. 27. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994;68:4400-4408.
28. 28. Fenyo EM, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
29. 29. Roos MTL, et al. Viral phenotype and immune response in primary human immunodeficiency virus type-1 infection. J Infect Dis 1992;165:427-432.
30. 30. Schuitemaker H, et al. Biological phenotype of human immunodeficiency virus type-1 clones at different stages of infection - progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations. J Virol 1992;66:1354-1360.
31. 31. Van't Wout AB, et al. Macrophage tropic variants initiate human immunodeficiency virus type-1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-2067.
32. 32. Schnitemaker H. Macrophage-tropic HIV variants - initiators of infection and AIDS pathogenesis. J Leukoc Biol 1994;56:218-224.
33. 33. Rudensey LM, Kimata JT, Benveniste RE, Overbaugh J. Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology 1995;207:528-542.
34. + T cell decline in vivo. Virology 1996;219:87-95.
35. 35. Tersmette M, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates - frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS related complex. J Virol 1988;62:2026-2032.
36. 36. Tersmette M, et al. Evidence of a role of virulent human immunodeficiency virus (H1V) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989;63:2118-2125.
37. 37. Ogg GS, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
38. 38. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse-transcriptase. Science 1988;242:1168-1171.
39. 39. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988;242:1171-1173.
40. 40. Nowak M. HIV mutation-rate. Nature 1990;347:522-522.
41. 41. Nowak MA, May RM. Mathematical biology of HIV infections - antigenic variation and diversity threshold. Math Biosci 1991;106:1-21.
42. 42. Nowak MA. Variability of HIV infections. J Theor Biol 1992;155:1-20.
43. 43. Nowak M, May RM. AIDS pathogenesis - mathematical models of HIV and SIV infections. AIDS 1993;7:S3-S18.
44. 44. Nowak MA. AIDS pathogenesis: from models to viral dynamics in patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:S1-S5.
45. 45. Wolinsky SM, et al. Adaptive evolution of human immunodeficiency virus type-1 during the natural course of infection. Science 1996;171:537-542.
46. 46. Hartung S. Boller K, Cichutek K, Norley SG, Kurth R. Quantitation of a lentivirus in its natural host - simian immunodeficiency virus in African-green monkeys. J Virol 1992;66:2143-2149.
47. 47. Nowak MA. et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
48. 48. Nowak MA, May RM, Sigmund K. Immune-responses against multiple epitopes. J Theor Biol 1995;175:325-353.
49. 49. Nowak MA. Immune-responses against multiple epitopes - a theory for immunodominance and antigenic variation. Semin Virol 1996;7:83-92.
50. 50. Gupta S, Maiden MCJ, Feavers IM, Nee S, May RM, Anderson RM. The maintenance of strain structure in populations of recombining infectious agents. Nat Med 1996;2:437-442.
51. 51. Gupta S, Ferguson N, Anderson R. Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents. Science 1998;280:912-915.
52. 52. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility complex (MHC) restriction and the capacity of IA to bind immunogenic peptides. Science 1987;235:1353-1358.
53. 53. Adorini L, Appella E, Doria G, Nagy ZA. Mechanisms influencing the immunodominance of T-cell determinants. J Exp Med 1988;168:2091-2104.
54. 54. Schaeffer EB, et al. Relative contribution of determinant selection and holes in the T-cell repertoire to T-cell responses. Proc Natl Acad Sci USA 1989;86:4649-4653.
55. 55. Liu ZR, Williams KP, Chang YH, Smith JA. Immunodominance - a single amino-acid substitution within an antigenic site alters intramolecular selection of T-cell determinants. J Immunol 1993;151:1852-1858.
56. 56. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T-cell antigenic determinants. Annu Rev Immunol 1993;11:729-766.
57. 57. Asjo B, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;20:660-662.
58. 58. Gruters RA, et al. Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS 1991;5:837-844.
59. 59. Ferbas J, et al. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J Virol 1996;70:7285-7289.
60. 60. Nowak MA, May RM. Coexistence and competition in HIV infections. J Theor Biol 1992;159:329-342.
61. 61. DeBoer RJ, Boerlijst MCB. Diversity and virulence thresholds in AIDS. Proc Nat Acad Sci USA 1994;91:544-548.
62. 62. Schenzle D. A model for AIDS pathogenesis. Stat Med 1994;13:2067-2079.
63. 63. Wodarz D, Klenerman P, Nowak, MA. Dynamics of cytotoxic T-lymphocyte exhaustion. Proc R Soc Lond Biol Sci 1998;265:191-203.
64. + T cells to death. Trends Microbiol 1993;1:207-209.
65. 65. Moss PAH, et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T-cells in peripheral-blood of infected donors. Proc Nat Acad USA 1995;92:5773-5777.
66. 66. Rinaldo CR, Beltz LA, Huang XL, Gupta P, Fan Z, Torpey DJ. Anti-HIV type I cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 1995;11:481-489.
67. 67. Rinaldo CR, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long term nonprogressors. J Virol 1995;69:5838-5842.
68. 68. Jameson SC, Carbone FR, Bevan MJ. Clone specific T-cell receptor antagonists of major histocompatibility complex class-1 restricted cytotoxic T cells. J Exp Med 1993;177:1541-1550.
69. 69. Bertoletti A, et al. Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-110.
70. 70. Klenerman P, et al. Cytotoxic T cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994;369:403-407.
71. 71. Meier UC, et al. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 1995;270:1360-1362.
72. 72. Jameson SC, Bevan MJ. T tell receptor antagonists and partial agonists. Immunity 1995;2:1-11.
73. 73. Kalams SA, Walker BD. Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Curr Top Microbiol Immunol 1995;202:79-88.
74. 74. Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol. 1995;25:1927-1931.
75. 75. Klenerman P, et al. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci USA 1996,93:15323-15328.
76. 76. McAdam SN, et al. Immunogenic HIV variant peptides that bind to HLA-B8 but fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-2736.
77. 77. Crowe SM, Kornbluth RS. Overview of HIV interactions with macrophages and dendritic cells - the other infection in AIDS. J Leukoc Biol 1994;56:215-217.
78. 78. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell-tropism as prognostic marker for disease progression in human immunodeficiency type-1 infection. J Clin Microbiol 1994;32:364-370.
79. 79. Mosier D, Sieburg H, Macrophage-tropic HIV - critical for AIDS pathogenesis. Immunol Today 1994;15:332-339.
80. 80. Crowe SM. Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Aust N Z J Med 1995;25:777-783.
81. 81. McKnight A, Clapham PR. Immune escape and tropism for HIV. Trends Microbiol 1995;3:356-361.
82. 82. Fauci AS. Host factors and the pathogenesis of HIV induced disease. Nature 1996;384:529-534
83. 83. Koot M, van't Wout AB, Koostra NA, deGoede REY, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type-1 infection. J Infect Dis 1996;173:349-354.
84. 84. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997;185:611-628.
85. 85. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA, Simmonds P. HIV tropism and coreceptor use. Nature 1997;385:495-496.
86. 86. Stevenson M, Gendelman HE. Cellular and viral determinants that regulate HIV-1 infection in macrophages. J Leukoc Biol 1994;56:278-288.
87. 87. Stevenson M. Portals of entry - uncovering HIV nuclear transport pathways. Trends Cell Biol 1996;6:9-15.
88. 88. Emerman M, Bukrinsky M, Stevenson M. HIV infection of non-dividing cells - reply. Nature 1994;369:108.
89. 89. Heinzinger NK, et al. The VPR protein of human immunodeficiency virus type-1 influences nuclear localisation of viral nucleic acids in non-dividing host cells. Proc Natl Acad Sci USA 1994;91:7311-7315.
90. 90. Stevenson M, et al. Identification of factors which govern HIV-1 replication in non-dividing host cells. AIDS Res Hum Retroviruses 1994;10:S82.
91. 91. Stevenson M, et al. Molecular basis for cell cycle dependent HIV replication. AIDS Res Hum Retroviruses 1995;11:S87.
92. 92. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, Stevenson M. Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci USA 1996;93:367-371.
93. 93. Wodarz D, Lloyd AL, Jansen VAA, Nowak MA. Dynamics of macrophage and T cell infection by HIV. J Theor Biol 1999;196:101-113.
94. 94. Dean M, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
95. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
96. 96. Huang YX, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
97. 97. Liu ZR, Williams KP, Chang YH, Smith JA. Immunodominance - a single amino-acid substitution within an antigenic site alters intramolecular selection of T-cell determinants. J Immunol 1993;151:1852-1858.
98. 98. Samson M, et al. Resistance to HIV 1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
99. 99. Balotta C, et al. Homozygous δ 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1 infected patient. AIDS 1997;11:F67-F71.
100. 100. Biti R, French RF, Young J, Bennetts B. Stewart G, Liang T. HIV 1 infection in an individual homozygous for the CCR-5 deletion allele. Nat Med 1997;3:252-253.
101. 101. Rana S, et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the δ CCR5 mutation. J Virol 1997;71:3219-3227.
102. 102. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV 1 infection in an individual homozygous for CCR5 δ 32. Lancet 1997;349:1219-1220.
103. 103. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differently expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
104. 104. Rowland-Jones S, Tan R. Control of HIV coreceptor expression: implications for pathogenesis and treatment. Trends Microbiol 1997;5:300-303.
105. 105. Unutmaz D, Littman DR. Expression pattern of HIV coreceptors on T cells: implications for viral transmission and lymphocyte homing. Proc Natl Acad Sci USA 1997;94:1615-1618.
106. 106. Loetscher P, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-345.
107. 107. Wodarz D, Nowak MA. The effect of different immune responses on the evolution of virulent CXCR4 tropic HIV. Proc R Soc Lond B Biol Sci 1998;265:2149-2158.
108. 108. O'Brien WA. HIV-1 entry and reverse transcription in macrophages. J Leukoc Biol 1994;56:273-277.
109. 109. Wodarz D, Nowak MA. Virus dynamics under different immune responses. J Theor Med; (In press).
110. 110. Tsang ML, et al. Neutralising antibodies against sequential autologous human immunodeficiency virus type-1 isolates after seroconversion. J Infect Dis 1994;170:1141-1147.
111. 111. Cornelissen M, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intra muscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol 1995;69:1810-1818.
112. 112. Lathey JL, Pratt D, Spector SA. Appearance of autologous neutralising antibody correlates with reduction in virus load and phenotype switching during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997;175:231-232.
113. 113. Nkengasong JN, et al. Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group OJ. Med Virol 1997;51:202-209.
114. + T-cells. Science 1995;270:1811-1815.
115. 115. Zanussi S, Dandrea M, Simonelli C, Tirelli U, Depaoli P Serum levels of RANTES and MIP-1 α in HIV positive long-term survivors and progressor patients. AIDS 1996;10:1431-1432.
116. 116. Gallo RC, Lusso P. Chemokines and HIV infection. Curr Opin Infect Dis 1997;10:12-17.
117. 117. Jansson M, et al. Sensitivity to inhibition by beta chemokines correlates with biological phenotype of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996;93:15382-15387.
118. 118. Nowak MA, McLean AR. A mathematical model of vaccination against HIV to prevent the development of AIDS. Proc R Soc Lond B Biol 1991;246:141-146.